Dusa Levulan
Executive Summary
Aminolevulinic acid photodynamic therapy for the treatment of multiple actinic keratoses of the face and scalp will be reviewed by FDA's Dermatologic & Ophthalmic Drugs Advisory Committee Nov. 5. FDA issued an "approvable" letter for Levulan June 28, pending revised product labeling and certification of GMP compliance at Dusa manufacturing sites. The committee will meet at the Holiday Inn in Gaithersburg, Md. beginning at 8:30 a.m